Abstract: An administering device capable of quantitatively spraying a multi-dose of powdered medicine includes a device body (1), a storage chamber (3) detachably provided in the device body, the storage chamber (3) being capable of storing powdered medicine, the amount of which corresponds to a plurality of administering operations, an accommodation chamber (10) capable of accommodating powdered medicine, the amount of which corresponds to a single administering operation, and a medicine dispensing rotor (6) movably attached to the device body. The medicine dispensing rotor communicates the accommodation chamber with the storage chamber at a charging position (3a) and communicates the accommodation chamber with the outside of the device body at an administering position (5a) so that the powdered medicine in the accommodation chamber can be administered. A cap (20) is provided for moving the medicine dispensing rotor between the charging position and the administering position.

Abstract: A preparation for intratracheobronchial administration comprising a powder preparation for intratracheobronchial administration contained in a receptacle composed essentially of hydroxypropyl methyl cellulose.

Abstract: A 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition comprising(a) a therapeutically effective amount of 1.alpha.,24-(OH).sub.2 --V.D.sub.3,(b) an oil phase component including(i) a solid oil component composed of 5 to 20 parts by weight of white petrolatum and 5 to 15 parts by weight of higher alcohols and(ii) a liquid oil component comprising of 3 to 10 parts by weight of squalane,(c) an aqueous phase component, and(d) 2.5 to 7.5 parts by weight at least two surfactants, wherein the 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition has a weight ratio of the solid oil component to the liquid oil component (i.e., solid oil component/liquid oil component) of at least approximately 2, the higher alcohols are composed of stearyl alcohol and cetyl alcohol, the weight ratio of the stearyl alcohol to the higher alcohols (i.e., stearyl alcohol/higher alcohols) is approximately 0.65 to approximately 0.

Abstract: A peptide proteinaceous drug nasal powder composition containing (i) an absorption accelerant comprised of a compound, or its salt, having in its molecule a group expressed by the formula (I): ##STR1## wherein, ##STR2## indicates a cyclohexane ring or a benzene ring which may be substituted at least one of its 3-position, 4-position, and 5-position and n is an integer of 1 to 3 and (ii) a therapeutically effective amount of a peptide proteinaceous drug.

Abstract: A biodegradable copolymer having the constituent units represented by the structures (I) and (II): ##STR1## wherein X represents a hydrogen atom, an acyl group having the formula RCO-- where R is a hydrocarbon group having 1 to 20 carbon atoms, an alkoxy group having to 20 carbon atoms, and Y represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, and m and n are independently integers of 1 or more, m+n is at least 10, and m/(m+n) is at least 0.01 and a pharmaceutical composition containing the same.

Abstract: An extemporaneous kit of pharmaceutical substance-containing fat emulsion which consists of a fat emulsion and (a) a pharmaceutical substance composition containing pharmaceutical substance and at least one solvent selected from the group consisting of water, liquid polyalkylene glycols, liquid alkylethanolamines, and liquid polyhydric alcohols, or (b) a pharmaceutical substance composition containing pharmaceutical substance and saccharides and/or 30 amino acids as an excipient, and a process for preparation of a pharmaceutical substance-containing fat emulsion therefrom.

Abstract: A solid calcitonin pharmaceutical composition comprised of a therapeutically effective amount of calcitonins and ethylene diamine tetraacetates.

Abstract: An aqueous preparation of active form of vitamin D.sub.3 which is solubilized with a nonionic surface active agent and stabilized with a combination of a specific chelating agent such as citric acid with an antioxidant. Stabilized oral and parenteral preparations of active form of vitamin D.sub.3 can be provided.

Abstract: A pharmaceutical solid preparation of active form of vitamin D.sub.3 of improved stability which comprises a composition of active form of vitamin D.sub.3 dispersed in an excipient readily soluble in organic solvent and a basic substance.As a basic substance, are cited sodium citrate, magnesium oxide or the like.

Abstract: An intranasally applicable powdery pharmaceutical composition comprising a polypeptide having a physiological activity, a quaternary ammonium compound, and a lower alkyl ether of cellulose. This powdery pharmaceutical composition has an excellent preservability and chemical stability of the polypeptides and, when the powdery composition is administered to the nasal cavity in the form of a spray, the polypeptides are effectively absorbed through the nasal mucosa.

Abstract: A composition for the injection of active type vitamins D.sub.3 comprising a lyophilized product of active type vitamins D.sub.3 and an excipient. This composition has good stability of active type vitamins D.sub.3 and is effective as an injection preparation.

Abstract: Pharmaceutical preparations for intraarterial administration use comprising highly fat soluble derivatives of 5-fluoro-2'-deoxyuridine having the antitumor activity and oleaginous bases, wherein the property of selectively migrating to the tumor tissue and the accumulating function of 5-fluoro-2'-deoxyuridine esters are remarkably improved.

Abstract: An antitumor agent comprising (i) at least one pyrimidine type nucleic acid derivative having the general formula (I): ##STR1## wherein X represents a fluorine atom or a trifluoromethyl group, R.sup.1 and R.sup.2 may be the same or different and represent a hydrogen atom or an acyl group, R.sup.3 represents a hydrogen atom or a hydroxyl group, and(ii) at least one 1-[(2-hydroxyethoxy)methyl]uracil derivative having the general formula (II): ##STR2## wherein Y represents a hydrogen atom, a halogen atom, a methyl group, a benzyl group, a benzyloxybenzyl group, a vinyl group, a nitro group, or an amino group and R.sup.4 represents a hydrogen atom or an acyl group.

Abstract: A process for treating psoriasis by externally applying to the skin of a warm-blooded animal a composition comprising:(A) a pharmaceutically effective amount of an active-type vitamin D.sub.3,(B) a substantially water-free carrier containing the active-type vitamin D.sub.3 dissolved or uniformly dispersed therein, and(C) a solvent selected from fatty acid esters, higher alcohols with 10 or more carbons and propylene carbonate.

Abstract: A method of inhibiting viral replication in a cell comprising administering an effective amount of an esterified derivative of 5-halogenated-2'-deoxy-uridine expressed by the following formula (I) ##STR1## wherein X represents any one of F, Cl, and Br; R.sup.1 and R.sup.2 may be identical or different from each other, each representing an aliphatic acyl group comprising two or more carbon atoms or an aromatic acyl group comprising 7 or more carbon atoms.

Abstract: A powdery pharmaceutical composition for application to the mucosa of the oral or nasal cavity including: (a) a base selected from the group consisting of lower alkyl ethers of cellulose; (b) a pharmaceutically effective amount of a drug selected from the group consisting of steroid or glycyrrhizic acid type anti-inflammatory agents; and (c) a stabilizer for the drug composed of at least one low irritant solid organic acid selected from the group consisting of saturated higher aliphatic monocarboxylic acids having 12 or more carbon atoms, aliphatic polycarboxylic acid, hydroxy aliphatic polycarboxylic acids, aromatic carboxylic acids, unsaturated lower aliphatic monocarboxylic acids having six or less carbon atoms, and cellulose derivatives having carboxyl group.

Abstract: A sustained release preparation comprising:(a) chitin, chitosan, or a mixture thereof(b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and(c) pharmaceutically active agents.This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.

Abstract: A pharmaceutical composition for external use with the enhanced penetration of a pharmacologically active agent through the skin or mucosa of a warm-blooded animal, said composition comprising(A) a pharmaceutically effective amount of the pharmacologically active agent, and(B) an optically active or inactive pyroglutamate of the following formula ##STR1## wherein R represents a linear, branched or cyclic alkyl or alkenyl group having 10 to 14 carbon atoms,as a penentration enhancer.

Abstract: This invention is concerned with an oral sustained release pharmaceutical preparation which is prepared as a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs, or a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs together with a foaming agent, so that it may release the active drugs by such slow degrees in the stomach or the intestinal tract as to make it possible to provide an adequate supply of active drugs in enough concentration to display their therapeutic value for many hours.

Abstract: A 5-fluoro-2'-deoxyuridine derivative expressed by the following formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different from each other, each representing an alkyl group of 1 to 18 carbon atoms having a carboxyl group as a substituent, or an alkyl group of 9 to 14 carbon atoms, or its pharmacologically acceptable salt as the active ingredient.Said 5-fluoro-2'-deoxyuridine derivative displays a high-level antitumor effect in low doses and shows outstanding safety.